Novartis Investigative site

Raleigh, North Carolina 27614

0 studies enrolling now · 42 studies all time

What they study most

Acute Heart Failure, Advancing Multiple Sclerosis, Asthma, COPD, Cancer, Carcinoma, Renal Cell, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Chronic Plaque-type Psoriasis, Coronary Artery Disease (CAD)

Studies at this site

• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma — Stopped early
• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma Patients — Stopped early
• Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma — Completed
• A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. — Completed
• Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder — Completed
• Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder — Completed
• To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma — Completed
• Efficacy, Safety, and Pharmacokinetics of QAW039 — Completed
• Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis — Completed
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone — Stopped early
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma — Completed
• Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) — Completed
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients. — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma — Completed
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation — Completed
• Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma — Completed
• NVA237 Versus Placebo 12-week Efficacy Study — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
• Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed
• Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma — Completed
• Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks — Completed
• Efficacy and Safety of Different Doses of Indacaterol — Completed
• Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol — Completed